Positive opinion granted for SC administration of KEYTRUDA for all adult indications approved in the European Union for KEYTRUDA Positive opinion also granted for KEYTRUDA as part of a perioperative ...

In June 2025, KEYTRUDA was approved in the U.S. for the treatment of adult patients with resectable LA-HNSCC whose tumors express PD-L1 (CPS ≥1) as determined by a Food and Drug Administration ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...

Merck has obtained the Food and Drug Administration’s permission for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and ...

The National Medical Products Administration (NMPA) has approved the OncoMate ® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic medical device in China. It is ...

(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, offering a ...

Keytruda Qlex is now FDA-approved for subcutaneous use in patients 12 and older with solid tumors, offering an alternative to IV administration. Subcutaneous administration can improve patient ...

The first immune checkpoint inhibitor that can be administered via subcutaneous injection in 1 to 2 minutes has emerged. Alteogen announced on the 20th that its partner Merck & Co., Inc., MSD, has ...

The FDA approved Merck's Keytruda Qlex, a new under-the-skin version of the cancer drug that can be injected in just 1-2 minutes, offering faster and more convenient treatment than traditional IV ...